Rege Nephro Co., Ltd.
PrivateLast Round
Debt
Jul 21, 2026
Total Funding Raised
$23.61M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Rege Nephro Co., Ltd. operates in Healthcare & Life Sciences and is based in Kyoto. Its latest recorded funding round was a Debt round in July 2026.
Rege Nephro Co., Ltd. is a biotechnology company that develops therapeutics and cell therapy for kidney, liver, and pancreas diseases using induced pluripotent stem cell (iPSC) technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rege Nephro Co., Ltd. Comparables
Compare Rege Nephro Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Trestle Biotherapeutics | 81% | |
| Orizuru Therapeutics, Inc. | 74% | |
| ProKidney Corp. | 70% |
For institutional investors. Book with your work email.
Rege Nephro Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Jul 21, 2026 | ||||
| Series B | Oct 7, 2024 | ||||
| Debt | Nov 1, 2023 | ||||
| Series A | Jan 31, 2022 | ||||
| VC Round | Jun 4, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Rege Nephro Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Chushin Venture Capital | Debt, Series B, Series A |
| JAFCO Group Co., Ltd. | Debt, Series B, Series A |
| TaiAn Technologies Corp. | Debt |
| 株式会社日本政策金融公庫 | Debt |
| Tohoku University Venture Partners | Series B |
| DCI Partners | Debt, Series B |
| 日本ベンチャーキャピタル株式会社 | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 21, 2026
$11M raised from Arcus South East Asia and others.
- Jun 18, 2026
Monthly visitors increased 57% MoM, reaching 2.6K.
For institutional investors. Book with your work email.
Rege Nephro Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Rege Nephro Co., Ltd.'s valuation, stock price, and market status.
Is Rege Nephro Co., Ltd. a public or private company?
Rege Nephro Co., Ltd. is a private company.
What is the current stock price of Rege Nephro Co., Ltd.?
Rege Nephro Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Rege Nephro Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Rege Nephro Co., Ltd. worth (valuation)?
Valuation information for Rege Nephro Co., Ltd. is not publicly available.
Can I buy Rege Nephro Co., Ltd. stock?
Rege Nephro Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Rege Nephro Co., Ltd.'s last funding round?
Rege Nephro Co., Ltd.'s most recent funding round was Debt on July 21, 2026.
Who are the main investors in Rege Nephro Co., Ltd.?
Key investors in Rege Nephro Co., Ltd. include DCI Partners.
Will Rege Nephro Co., Ltd. IPO soon?
No public IPO plans have been announced for Rege Nephro Co., Ltd..
How can I track Rege Nephro Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Rege Nephro Co., Ltd.'s shares on secondary markets.